Alector's Latozinemab Fails Phase III Trial for Frontotemporal Dementia, Company Cuts Workforce by Half
核心洞察
Alector's investigational antibody latozinemab failed to slow disease progression in a 96-week Phase III trial for frontotemporal dementia (搜索) caused by progranulin gene mutations.
Despite significantly increasing progranulin biomarker levels, the GSK-partnered drug showed no clinical benefit versus placebo and missed all secondary endpoints.
The failure prompted Alector to discontinue the drug program, lay off 49% of its workforce, and led to a 51% stock price drop.
Alector announced Tuesday that its investigational antibody latozinemab has failed a pivotal Phase III trial for frontotemporal dementia (搜索), prompting the company to discontinue the program and eliminate nearly half its workforce. The disappointing results from the INFRONT-3 trial sent shares plummeting 51% to $1.57 in after-hours trading.
Trial Results and Clinical Impact
The 96-week INFRONT-3 trial evaluated latozinemab in patients with frontotemporal dementia (搜索) (FTD) caused by progranulin gene mutations. While the drug demonstrated a "significant effect" on progranulin levels—a biomarker linked to FTD—it failed to slow disease progression compared to placebo on the primary endpoint.
The antibody also missed key secondary endpoints, showing no treatment effect on volumetric magnetic resonance imaging outcomes and other fluid biomarker concentrations. These results have raised fundamental questions about the therapeutic approach.
"The findings suggest restoring [progranulin] does not translate to clinical benefit in this trial/patient population," William Blair analysts wrote to investors, calling the Phase III outcome "disappointing."
Corporate Restructuring and Leadership Changes
The trial failure has triggered a comprehensive strategic review at Alector. The company is laying off approximately 49% of its workforce, affecting around 116 of its 238 full-time employees as of the end of 2024.
Sara Kenkare-Mitra, Alector's president and R&D head, will leave her position effective December 22 "to pursue new leadership opportunities." She will remain with the company through the transition period.
Alector has discontinued the planned open-label extension portion of the INFRONT-3 trial and canceled a continuation study of latozinemab. The company plans to conduct an in-depth analysis of the trial data and present findings at an upcoming medical meeting.
Drug Development Background
Previously known as AL001, latozinemab is a monoclonal antibody designed to modulate progranulin protein levels. Progranulin serves as a key regulator of immune activity in the brain and has been linked to frontotemporal dementia (搜索) development.
The drug was developed under a partnership with GSK established in July 2021, which included $700 million upfront and up to $1.5 billion in potential milestone payments. The collaboration focused on co-developing latozinemab and another progranulin modulator, AL101, for neurodegenerative diseases.
Ongoing Programs and Financial Position
Despite the latozinemab setback, the GSK partnership continues. AL101 (nivisnebart (搜索)) remains in development, currently being evaluated in the Phase II PROGRESS-AD trial for patients with early Alzheimer's disease (搜索). The study is scheduled to complete next year, with an independent interim analysis planned for the first half of 2026.
As of September 30, Alector maintained $291.1 million in cash, cash equivalents, and short-term investments, providing runway through 2027 according to company statements.
Market Response and Analyst Perspectives
The trial failure prompted immediate downgrades from Wall Street analysts. TD Cowen's Yaron Werber, who previously recommended buying Alector shares, downgraded the stock to "hold," stating he would "move to the sidelines."
The results have cast doubt on the "clinical translatability" of targeting plasma progranulin concentrations as a therapeutic strategy. With this uncertainty "and a lack of other near-term catalysts, we prefer a wait-and-see stance" on the stock, Werber noted.
This setback follows another recent disappointment for Alector. In late 2024, the company discontinued AL002, an antibody developed with AbbVie (搜索) for Alzheimer's disease (搜索), after it failed a Phase II trial, resulting in a 17% workforce reduction at that time.